德康医疗(DXCM)盘前股价大跌5.81%,引发市场关注。公司公布的第三季度财报虽然超出华尔街预期,但重申了较为保守的2024年全年销售预期,这引发了投资者对该公司未来增长前景的担忧。
德康医疗第三季度实现营收3.45亿美元,同比增长29%,主要得益于其连续性血糖监测设备在糖尿病患者中的强劲需求。不过,公司也重申了2024年全年销售额约为40亿至40.5亿美元的预期。
多位分析师认为,这一全年销售预期略显保守,意味着公司增长可能放缓,导致投资者担心未来业绩前景不佳。一些投资者担忧,如果公司在销售团队重组、客户流失等问题未完全解决,增长动力或将继续减弱。受此影响,投资者纷纷抛售德康医疗股票,推动该股盘前大跌5.81%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."